Howe, Charles L <br/><br/>
Subcutaneous IGF-1 is not beneficial in 2-year ALS trial.  [electronic resource] 

 -  Neurology  Oct 2009 
 - 1247; author reply 1247-8 p.  digital 
<br/><br/> Publication Type: Comment; Letter 
<br/><br/><label>ISSN: </label>1526-632X 
<br/><br/><label>Standard No.: </label>10.1212/WNL.0b013e3181b26ae6  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Amyotrophic Lateral Sclerosis--drug therapy<br/>Animals<br/>Clinical Trials as Topic<br/>Humans<br/>Injections, Subcutaneous<br/>Insulin-Like Growth Factor I--administration & dosage